Identification of the gene for vitamin K epoxide reductase
By Tao Li, Chun-Yun Chang, D. Jin, P. Lin, Anastasia Khvorova, D. Stafford. Nature, 2004
745 citations recorded by the source corpus.
Subfields: Biochemistry, Nutrition and Dietetics, Pharmacology
View Paper: https://www.semanticscholar.org/paper/16e7516211cec83496757b6e5b2387d7c7801e3a
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Pharmacology
Citations in the corpus
- Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. (2005, background): “Exclusion criteria were Asian or African descent (36 patients), management by telephone rather than in person (185), absence of verbal and written consent (5), absence of a blood specimen (3), and absence of a confirmed date of initial exposure to warfarin (11).”
- A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. (2005, neutral): “GG, n 67, 45.5% 31/36 49/11/7 44.2 (18.0) 1.5 (1.3) 5.2 (2.6)† 2.52 (0.35) 42.7 (23) 26.6 (21.9) GA, n 58, 39.5% 35/23 42/11/5 46.2 (15.1) 1.7 (2.8) 5.3 (2.2) 2.60 (0.45) 24.3 ( 25 ) 25.5 (21.6) AA, n 22, 15.0% 14/8 21/1/0 44.3 (16.5) 1.6 (1.6) 6.9 (4.0) 2.38 (0.31) 36.6 (7) 28.9 (26.6)”
- Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study (2006, neutral): “identified [14].”
- The high-affinity HSP90-CHIP complex recognizes and selectively degrades phosphorylated tau client proteins. (2007, result): “These siRNAs were pooled in all subsequent studies, consistent with the work of others (26, 27).”
- Clinical Pharmacogenetics Implementation consortium Guidelines for CYP2C9 and VKORC1 Genotypes and Warfarin Dosing (2011, neutral): “[45, 78] high”
- Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). (2008, background): “Subsequently, mutations in this gene have been identified, leading to enzymes with varying sensitivities to inhibition by warfarin, 45,46–50 thereby affecting the pharmacodynamics of warfarin.”